PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNoticescategoryCategories
BuyersSuppliersNoticesCategories
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. Outlook Therapeutics, Inc.
OT

Outlook Therapeutics, Inc.

Guildford
SME
outlooktherapeutics.com ↗
Compare peers
Awarded
£688.8m
Live
1
Buyers
2
12m
£688.8m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts1 / 2
  • Top buyers2
  • Category mix
  • Geography
  • Peers
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — Outlook Therapeutics, Inc.Updated 20 Jul 2026

At a glance · for buyers and watchdogs

Outlook Therapeutics, Inc. has won £688.8m across 2 public-sector buyers, with 1 live contract. No active Companies House risk flags.

Why: top buyer NHS England North East and Yorkshire Health and Justice at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
1 of 2Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value

Commitments mapped to the Government Social Value Model themes.

⚑ Self-reported
—

No social-value commitments yet

Jobs, skills, environmental, inequality and community commitments appear here once a claimed supplier attributes them to awarded contracts, or once we detect them on the supplier’s website.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

⚑ Self-reported & from notices

Service tags, sectors served and target geographies appear here once a supplier verifies ownership of this profile.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 1 live · 1 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England North East and Yorkshire Health and Justice—01 Dec 2025£688.8m1.5 yrspending
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England————Live
Total live value — · mean award £344.4m

Top buyers · 2 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England North East and Yorkshire Health and Justice
1 contract
100%
since 2025
2
NHS England
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire2 contracts
100%

Peers

Suppliers with overlapping CPVs and buyers.

✓ From notices
≈

No close peers found

Not enough categorised awards yet to compute a comparable peer set.

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Due in -23d
Next due 30 Jun 2026
Confirmation statement
Up to date
Next due 14 Sept 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
08179857
Status
Active
Type
Private limited
Incorporated
14 Aug 2012
Reg. office
3rd Floor One London Square, Cross Lanes, Guildford, Surrey, GU1 1UN
SIC codes
72110
Last accounts
30 Sept 2024
Next accounts due
30 Jun 2026

Directors & PSC

  • JAHR, Robert Charles — director
    Appointed 04 Feb 2026
  • KENYON, Lawrence — director
    Appointed 23 Jul 2019
  • Outlook Therapeutics Nl B.V. — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
OUTLOOK THERAPEUTICS LTD
08179857 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.